Remisid (nimesulide) gel 1% 30 g.


Local treatment of pathological conditions of the musculoskeletal system characterized by pain, inflammation and stiffness of movements, such as osteoarthritis, periarthritis, post-traumatic tendinitis, tendosinoviti, muscle sprain, heavy physical loads on the joints.



The drug Remisid is produced in the form of a homogeneous translucent gel, yellow or yellowish-green in color with a weak specific odor.
The active ingredient is a part of 1 g: nimesulide 10 mg.
Additional substances: dimethyl sulfoxide, levomenthol, propylene glycol, macrogol 400, trometamol, carbomer 980, purified water.

Release form
One pack contains one tube with gel (30 g).

Pharmacological properties
Remisid belongs to the group of non-steroidal anti-inflammatory drugs intended for topical use, which have analgesic, antipyretic effects and relieve the inflammatory process. The drug causes the disappearance or reduction of pain in the area of ​​application of the gel, including pain in the joints, during movement and at rest, reduces swelling of the joints and morning stiffness, and also promotes greater range of motion.

Indications for use
The drug Remisid is used and prescribed as a local treatment of pathologies of the musculoskeletal system, which are characterized by inflammation, pain and stiffness of movement, such as: periarthritis, osteoarthritis, post-traumatic tendonitis, muscle strain, tendosynovitis and heavy physical stress on the joints.

The drug Remisid is contraindicated for use in: infectious skin diseases, dermatitis, damage to the epidermis, as well as in the presence of hypersensitivity to the constituent components and in childhood. Do not use the gel in patients with allergic reactions (rhinitis, bronchospasm, urticaria) to acetylsalicylic acid or other drugs that inhibit prostaglandin synthesis.
The drug is used with extreme caution in: congestive heart failure, impaired liver and kidney function, ulcers in the acute stage, gastroduodenal bleeding or severe blood coagulation disorders and in old age.

Pregnancy and breastfeeding period
The use of the drug Remisid is contraindicated in pregnant women and nursing mothers.

Mode of application
The drug Remisid is intended for external use.
The gel is applied in a thin layer on painful areas of the body and lightly rubbed into the skin 3-4 times a day with massage movements.
The duration of therapy is determined for each patient individually, depending on the effectiveness of treatment, but not more than 1 month.
Wash and dry the skin before applying the gel.
Do not use the drug on damaged skin, on open wounds, under airtight dressings, and avoid getting the gel on the mucous membranes and eyes.

If you use Remisid gel in doses that significantly exceed the recommended dosages or on large areas of the skin, such overdose symptoms are possible: headache, dizziness, dyspepsia and pain in the epigastric region.
If any signs of intoxication appear, symptomatic treatment should be applied, the drug should be discontinued or the dose should be reduced.

Adverse reactions
The use of Remisid gel can cause skin irritation (rash, erythema, itching, peeling, allergic reactions), and sometimes anaphylactic reactions in the form of Quincke, suffocation, vasomotor rhinitis, bronchospasm are possible.

Storage conditions
The drug Remisid must be stored at a temperature not exceeding +25 ° C, in its original packaging, out of direct sunlight and access to children.
The shelf life is 24 months.